外周炎症相关标志物与非小细胞肺癌患者免疫治疗及预后相关

日嘎 乌(承德医学院附属医院肿瘤科，中国)
慧 张(承德医学院附属医院肿瘤科，中国)
喜英 吕(承德医学院附属医院肿瘤科，中国)

摘要

随着免疫治疗在非小细胞肺癌（ NSCLC）患者中的应用越来越广泛，外周炎症因子与免疫治疗预后之间的关系也引起了越来越多的关注。常见的预测标志物包括肿瘤突变负荷（ TMB）和程序性死亡蛋白配体1（ PD-L1）表达量，这些指标检测成本较高且表达水平不易控制。目前仍缺乏简单、有效、便宜、易获得的预后因子。外周炎症相关标志物，如中性粒细胞与淋巴细胞比值（ NLR）、衍生中性粒细胞与淋巴细胞比值（ dNLR）、血小板与淋巴细胞的比值（ PLR）、淋巴细胞与单核细胞比值（ LMR）、乳酸脱氢酶（ LDH）、肺免疫预后指数（ LIPI）以及T淋巴细胞亚群有望成为非小细胞肺癌患者预后评估的有效指标，对准确评估病情、识别生存风险、改善远期预后具有现实意义。

关键词

非小细胞肺癌；免疫治疗； NLR； PLR；淋巴细胞亚群

参考

Sung H, Ferlay J, Siegel R L, et al. Global Cancer Statistics 2020:

GLOBOCAN Estimates of Incidence and Mortality Worldwide

for 36 Cancers in 185 Countries[J]. CA: A Cancer Journal for

Clinicians,2021,71(3):209-249.

Hayashi H, Nakagawa K. Combination therapy with PD-1 or

PD-L1 inhibitors for cancer[J]. International Journal of Clinical

Oncology, 2020,25(5):818-830.

Wojas-Krawczyk K, Kalinka E, Grenda A, et al. Beyond PD-L1

Markers for Lung Cancer Immunotherapy[J]. International Journal

of Molecular Sciences,2019,20(8):1915.

Aloe C, Wang H, Vlahos R, et al. Emerging and multifaceted

role of neutrophils in lung cancer[J]. Translational Lung Cancer

Research,2021,10(6):2806-2818.

Xie X, Liu J, Yang H, et al. Prognostic Value of Baseline

Neutrophil-to-Lymphocyte Ratio in Outcome of Immune

Checkpoint Inhibitors[J]. Cancer Investigation,2019,37(6):265-274.

Wen S, Du X, Chen Y, et al. Association between changes in

thioredoxin reductase and other peripheral blood biomarkers with

response to PD-1 inhibitor-based combination immunotherapy in

non-small cell lung cancer: a retrospective study[J]. Translational

Lung Cancer Research,2022,11(5):757-775.

Chen Y, Wen S, Xia J, et al. Association of Dynamic Changes

in Peripheral Blood Indexes With Response to PD-1 InhibitorBased Combination Therapy and Survival Among Patients

With Advanced Non-Small Cell Lung Cancer[J]. Frontiers in

Immunology,2021(12):672271.

Cao D, Xu H, Xu X, et al. A reliable and feasible way to predict the

benefits of Nivolumab in patients with non-small cell lung cancer:

a pooled analysis of 14 retrospective studies[J]. Oncoimmunology,

,7(11):e1507262.

Lu X, Wan J, Shi H. Platelet-to-lymphocyte and neutrophilto-lymphocyte ratios are associated with the efficacy of

immunotherapy in stage III/IV non-small cell lung cancer[J].

Oncology Letters,2022,24(2): 266.

Mezquita L, Preeshagul I, Auclin E, et al. Predicting immunotherapy

outcomes under therapy in patients with advanced NSCLC using

dNLR and its early dynamics[J]. European Journal of Cancer51

(Oxford, England: 1990),2021(151):211-220.

Lim J U, Kang H S, Yeo C D, et al. Predictability of early changes

in derived neutrophil-to-lymphocyte ratio and neutrophil-tolymphocyte ratio in patients with advanced non-small cell lung

cancer treated with immune checkpoint inhibitors[J]. Journal of

Thoracic Disease,2021,13(5):2824-2832.

D S, A A. Platelet-Leukocyte Interplay in Cancer Development and

Progression[J]. Cells,2020,9(4)[2022-11-17].

Bilen M A, Martini D J, Liu Y, et al. The prognostic and

predictive impact of inflammatory biomarkers in patients who

have advanced-stage cancer treated with immunotherapy[J].

Cancer,2019,125(1):127-134.

Kartolo A, Holstead R, Khalid S, et al. Serum neutrophil-tolymphocyte ratio and platelet-to-lymphocyte ratio in prognosticating

immunotherapy efficacy[J]. Immunotherapy,2020,12(11):785-798.

Zhou K, Cao J, Lin H, et al. Prognostic role of the platelet to

lymphocyte ratio (PLR) in the clinical outcomes of patients with

advanced lung cancer receiving immunotherapy: A systematic review

and meta-analysis[J]. Frontiers in Oncology,2022(12):962173.

Pavan A, Calvetti L, Dal Maso A, et al. Peripheral Blood Markers

Identify Risk of Immune-Related Toxicity in Advanced Non-Small

Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors[J].

The Oncologist,2019,24(8):1128-1136.

Ravindranathan D, Master V A, Bilen M A. Inflammatory Markers

in Cancer Immunotherapy[J]. Biology,2021,10(4):325.

Reynders K, De Ruysscher D. Tumor infiltrating lymphocytes in

lung cancer: a new prognostic parameter[J]. Journal of Thoracic

Disease,2016,8(8):e833-e835.

Rossi S, Toschi L, Finocchiaro G, et al. Neutrophil and lymphocyte

blood count as potential predictive indicators of nivolumab

efficacy in metastatic non-small-cell lung cancer[J]. Immunothera

py,2020,12(10):715-724.

Sekine K, Kanda S, Goto Y, et al. Change in the lymphocyte-tomonocyte ratio is an early surrogate marker of the efficacy of

nivolumab monotherapy in advanced non-small-cell lung cancer[J].

Lung Cancer (Amsterdam, Netherlands),2018(124):179-188.

Wang S, Sun J, Chen K, et al. Perspectives of tumorinfiltrating lymphocyte treatment in solid tumors[J]. BMC

Medicine,2021(19):140.

吴翠华.PD-1单抗治疗非小细胞肺癌的疗效及对免疫功能的分

析[J].世界复合医学,2021,7(10):14-17.

曹丹.免疫联合化疗方案治疗PD-L1高表达晚期NSCLC患者的

效果及对生存率的影响[J].中国医学创新,2022,19(9):144-147.

王芸,王郁阳,姜曼,等.帕博利珠单抗对晚期非小细胞肺癌患者T

淋巴细胞亚群的影响及疗效观测[J].中国肺癌杂志,2021,24(3):

-187.

牛越,石晓宇.外周血淋巴细胞亚群检测在肺癌患者临床评估及

辅助治疗中的意义[J].实用癌症杂志,2019,34(5):785-787+791.

Mishra D, Banerjee D. Lactate Dehydrogenases as Metabolic Links

between Tumor and Stroma in the Tumor Microenvironment[J].

Cancers,2019,11(6):750.

Zhang Q, Gong X, Sun L, et al. The Predictive Value of

Pretreatment Lactate Dehydrogenase and Derived Neutrophilto-Lymphocyte Ratio in Advanced Non-Small Cell Lung Cancer

Patients Treated With PD-1/PD-L1 Inhibitors: A Meta-Analysis[J].

Frontiers in Oncology,2022(12):791496.

Criscitiello C, Marra A, Morganti S, et al. Pretreatment Blood

Parameters Predict Efficacy from Immunotherapy Agents in Early

Phase Clinical Trials[J]. The Oncologist,2020,25(11):e1732-e1742.

Meyers D E, Stukalin I, Vallerand I A, et al. The Lung Immune

Prognostic Index Discriminates Survival Outcomes in Patients

with Solid Tumors Treated with Immune

DOI: http://dx.doi.org/10.12345/yzlcyxzz.v6i12.14885